Table 2.

Extracellular vesicles as delivery carriers for targeted cancer therapy.

Donor	Cargo	Cancer type	Target	Outcome	Ref
DCs	Ovalbumin, LPS and IFN-γ	T cell carcinoma	Macrophages, DCs and T cells	Boosted both innate and adaptive immunity	(Matsumoto et al., 2020)
Breast cancer cells	miR-126	Lung cancer	A549 cells	Inhibiting lung metastasis	(Nie et al., 2020)
BM-MSCs	miR-375	Cervical cancer	Cervical cancer cells	Discover new biomarkers for cervical cancer treatment	(Ding et al., 2020)
Human liver stem cells	miR-145 and miR-200	Renal cell carcinoma	Renal cancer stem cells	Inhibiting tumor growth	(Brossa et al., 2020)
HEK-293 cells	HN3 protein	Liver cancer	GPC3 + HuH-7 cancer cells	Effectively targeting liver cancer cells and inhibiting tumor growth	(He et al., 2020)
DCs	CD9 and CD63	Lung cancer	T cells and T cell subset populations	Induced immune responses	(Than et al., 2020)
DCs	E749-57 peptide	Cervical cancer	CD8+ T cells	Induced protective immunity responses to cervical cancer	(Chen et al., 2018)
Human breast cancer cells	PTX-linoleic acid prodrug and CuB	Breast cancer	CTCs	Inhibiting tumor regression and metastasis	(Wang et al., 2020)
BM-MSCs	Let-7	Lung cancer	KDM3A/DCLK1/FXYD3 axis	Significantly suppressing cancer proliferation, migration and invasion	(Liu et al., 2021)
Breast cancer cells	miRNAs (Let-7i, miR-142 and, miR-155)	Breast cancer	DCs and T cells	Inhibiting of solid tumors	(Khani et al., 2021)
Hepatocellula carcinoma cells	miR30a-3p	Hepatocellular carcinoma	SNAP23 gene	Effectively attenuating HCC migration, invasion, and metastasis	(Liu et al., 2021)